SAN DIEGO, Nov. 10, 2014 /PRNewswire-iReach/ -- eLux Medical, Inc.
eLux Medical, Inc. nominated as Falling Walls Science Start Up of 2014 .
eLux Medical, Inc., developer of NanoLipo, a novel nanomedicine approach to liposuction, is pleased to announce their selection as one of 25 companies nominated world wide for the 'Falling Walls Science Start Up of 2014'. The nominees will be present Saturday November 8th at The Falling Walls Venture in Berlin Germany, commemorating the 25th anniversary of the Fall of the Berlin Wall. Falling Walls Venture is an international forum for outstanding science based start-up companies, venture capitalists and strategic investors as well as their wider academic environment. 25 leading academic institutions and venture capitalists present their most outstanding science based enterprises to an audience and a distinguished jury.
Handelsblatt titles the Falling Walls Conference "the most exceptional science conference in the world" and the BBC suggests to meet the "brightest minds on the planet". Each year on 9 November, a select and diverse audience of 600 international decision makers in politics, business, science, media and culture from more than 75 nations convenes in Berlin to see which walls will fall next in science and society.
Adah Almutairi, eLux's Founder and Chief Technology Officer Said,
"We are honored to be nominated by this distinguished jury of venture capitalists and private equity judges, gathered on this special occasion to help shape the future of science start ups."
About eLux Medical, Inc.
eLux Medical Inc., together with engineers from the University of California, San Diego (UCSD) and the top US doctors in liposuction, is developing NanoLipo, a novel gold assisted liposuction, which is poised to disrupt the cosmetic surgery market and will allow: Double the amount of fat removed in half the procedure time. Preclinical studies at UCSD of our patent pending system show superior clinical, aesthetic and economic benefits for both patients and physicians.
About Forward-Looking Statements
The Company cautions you that the statements included in the press release that are not a description of historical facts are forward-looking statements. These include statements regarding the potential clinical benefits of NanoLipo and the commercial prospects of eLux Medical, Inc. NanoLipo is an investigational device and is not approved for sale in the USA or any other country.
CONTACT
Adah Almutairi, Founder
858 232 7848
adah.almutairi@eluxmedical.com
MEDIA
Chris Smith
858-220-6939
Media Contact: chris smith, eLux Medical Inc,, 8582206939, chris@eluxmedical.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE eLux Medical, Inc.
